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Regional Differences
Invalidate U.S. Sperm Trend
Conclusions
Regarding the continuing debate in EHP
over the question ofwhether or not human
sperm densities have declined in the
United States, I feel compelled to respond
to the statement bySwan et al. (1) that
regional variation would not be inconsistentwith
the average decline that we demonstrated in
Europe and the United States.
In referring to regional variation in sperm
densities, Swanetal. cite theworkofFisch et
al. (2) as indicating that sperm counts have
not declined in the United States. In this
study, sperm counts were analyzed in Los
Angeles, California; Roseville, Minnesota;
and New York, New York. A study by
MacLeod and Wang (3) indicates that
sperm counts have remained constant in
New York since 1938. In addition, two
other published studies report that sperm
counts have not dedined in Wisconsin (4)
or in Seattle, Washington (5). There is not a
single studyofhealthymen from anyfertility
center or sperm bank that has reported a
decline inspermcounts intheUnitedStates.
The regional variation in sperm counts,
with a nearly twofold difference in average
sperm counts between Los Angeles and
New York, invalidates any study that
attempts to demonstrate a twofold decline
in sperm counts based on trends over time
in reporting of sperm counts from differ-
ent regions of the United States (6).
Despite the assertion ofSwan et al. (7) that
the data are robust, there can be no valid
demonstration of a twofold decline in
sperm counts in the United States when
normal sperm counts vary nearly as much
between LosAngeles and NewYork.
John Heinze
JohnAdamsAssociates
Washington, D.C.
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On "Scents and Sensitivity"
I was delighted to learn ofthe informative
article, "Scents and Sensitivity" [EHP
106:A594-A599 (1998)]. I would like to
see this issue get the major media coverage
itwarrants.
Being extremely sensitive to fragrances,
I have been seeking accommodation for
over two years in the large office where I
work. I was recently granted a private
office space (without a door) and the firm
purchased an air cleaner (HEPA with car-
bon pre-filter) for myuse.
My employers' bottom line is that they
areunwilling to requestpeople toforego use
ofpersonal scented products in the office. I,
however, am unwilling to wear a face mask
all day in a work environment that would
not, by nature ofthe work being done here,
requireanyone towear amask.
Ifagovernment agencywere to publidy
recognize that there is a health risk to some
people from chemically based fragrances,
offices such as the one where I work would
be able to restrict use of scented personal
products. The health of people such as
myself would be greatly benefited and no
onewouldbe injuredbythe omission.
PeggyDavis
Atlanta, Georgia
Chiorpyrifos (Dursban) and
Dow Employees
Papers published in EHP concerning
adverse effects of pesticide exposure have
helped protect the public's health. These
include the study by Guillette et al. (1)
concerning learning impairment in young
children exposed to pesticides; the birth
defects-pesticides study by Garry et al. (2;
brain tumors in pesticide-exposed children
(3); and the studybyGurunathan et al. (4)
demonstrating volatilization and condensa-
tion ofDursban onto indoor surfaces, thus
potentiating exposure.
The artide by Gibson et al. (5) in the
June issue ofEHPraises a number oftrou-
bling questions. The authors failed to cite
the reasons for EPA restrictions on the use
of (chlorpyrifos) Dursban (6,7) and the
EPA report that reviewed thousands of
adverse reports to the EPAand poison con-
trol centers (8).
Gibson et al. (5) allege that chlorpyrifos
is notmutagenic. Ofthe28 Dursban toxicity
tests reported in the EPA database for 1996,
19 were negative for gene mutation, 3 were
positive for DNA damage, 1 was positive for
aneuploidy, and 2were positive for micronu-
cleus disruption (9). Genetic damage was
seen inapplicators ofpesticdes (10).
Gibson et al. (5) daim that chloripyrifos
is not teratogenic and does not adversely
affect reproduction. In November 1996,
under Section 6(a)(2) of the Federal
Insecticide, Fungicide, and Rodenticide Act
(FIFRA), DowElanco itself reported 12
adverse reproductive effects to the EPA as a
part of its late adverse reaction reports. A
yearlater, Dowreported athirteenthhuman
case and adverse reproductive outcome in a
breeder dog (11). The material safety data
sheetforDursbanTC (12) states,
Fetotoxicity and fetal development abnormalities
were observed in a chronic ingestion study of
pregnant mice, but the same dose produced severe
maternal toxicity.
Chlorpyrifos, the pesticidal agent in
Dursban, is both a chlorinated and
organophosphate chemical, with toxicity
characteristics of each class of chemicals.
The product Dursban is a complex mix-
ture, containing sulfotepp and trichloropy-
ridinol (TCP) in addition to chlorpyrifos.
TCP is used to manufacture chlorpyrifos,
is found in the commercial product, is the
metabolic breakdown product, and has
been reported to be teratogenic at doses
that are nontoxic to the mother (13,14).
Goldsmith et al. (15) reported birth
defect cases in Israel. These pesticide expo-
sures included Dursban, and were also
reported directly to the U.S. EPA (16). Still
Dow has been reluctant to accept the con-
cept that exposure to a chlorinated
organophosphate chemical designed to kill
insects by interfering with neurological
function could harm the developing
human. Whitney et al. (17) reported specif-
ic cellular mechanisms for developmental
neurotoxicity.
Gibson et al. (5) cited only four chil-
dren with birth defects [see Sherman (18)].
There actually were eight children with
birth defectswho had beenexposed in utero
to Dursban (15)). Discussing the findings,
Gibson et al. (5) daimed lackof"consisten-
cy of symptoms among the children."
Actually, the findings are not symptoms,
but actual defects, and there is astrong pat-
tern, calculated at odds of1045 for the first
fourchildren (20). Tabulation ofeight chil-
dren demonstrates a consistent pattern (see
Table 1). In keeping with standard scientif-
ic methodology, other causes of birth
defects have been explored (seeTable 2).
Gibson et al. (5) state that I said "the
mother's exposures to chlorpyrifos hap-
pened too late in the child's development
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